The abstract is read at the publisher; the summary is JClub's.
Clopidogrel plus aspirin initiated within 72 hours after mild ischemic stroke or transient ischemic attack reduces new stroke in F2R IVSn-14 T-allele carriers (HR 0.77).
- Why it matters: Genetic differences in PAR-1 signaling may influence how well clopidogrel prevents recurrent ischemic events, but the effect of F2R variants under a 72-hour initiation window was unclear.
- What they did: In a secondary analysis of the INSPIRES randomized trial in China (5791 patients; 222 centers; 2018–2022), investigators tested interaction between treatment and F2R IVSn-14 (AT/TT vs AA) using Cox models for new stroke and 90-day bleeding.
- The result: New stroke fell with clopidogrel-aspirin versus aspirin alone in AT/TT patients (7.1% vs 9.2%; HR 0.77, P=0.02) but not in AA patients (HR 0.95, P=0.75); moderate-to-severe bleeding was not significant in either genotype.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.